Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Blood (2019) 134 (Supplement_1): 5296.

https://doi.org/10.1182/blood-2019-121997

Published: 2019

Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD

Blood (2019) 134 (Supplement_1): 1040.

https://doi.org/10.1182/blood-2019-124876

Published: 2019

Journal Articles

Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

Franck Morschhauser, MD PhD, Ahmad Awada, MD PhD, Jean-Pascal Machiels, MD PhD, Gilles Andre Salles, MD PhD, Sylvie Rottey, MD PhD, Simon Rule, MD, David Cunningham, MD FRCP, Frederic Peyrade, MD, Christophe Fruchart, MD, Hendrik-Tobias Arkenau, MD PhD, Isabelle Genvresse, MD, Li Liu, PhD, Christoph Kneip, PhD, Carol Pena, PhD, Joachim Grevel, PhD, Jun Zhang, PhD, Galia Cisternas, PhD, Susanne Reschke, MSc, Camille Granvil, PhD

Blood (2017) 130 (Supplement 1): 1256.

https://doi.org/10.1182/blood.V130.Suppl_1.1256.1256

Published: 2017

Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim

Blood (2017) 130 (Supplement 1): 4128.

https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128

Published: 2017

Journal Articles

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood (2016) 128 (22): 624.

https://doi.org/10.1182/blood.V128.22.624.624

Published: 2016

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

Journal Articles

The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma

Kenichi Miyamoto, MD, Takashi Watanabe, MD PhD, Hideaki Kitahara, MD, Masashi Wakabayashi, MSc, Kenichi Nakamura, MD, Yuko Watanabe, Dai Maruyama, MD PhD, Kensei Tobinai, MD, PhD, Kunihiro Tsukasaki, MD, Haruhiko Fukuda, MD

Blood (2016) 128 (22): 4779.

https://doi.org/10.1182/blood.V128.22.4779.4779

Published: 2016

Journal Articles

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Adam M. Petrich, MD, Leo I. Gordon, MD, Jeffrey R. Infante, MD, Sumit Madan, MD, Francis J. Giles, MD, Halla S. Nimeiri, MBBS, Jason B. Kaplan, MD, Kate Stumpo, Bin Zhang, ScD, Stephanie Faucette, PharmD, PhD, Yaping Shou, MD PhD, Kent C. Shih, MD

Blood (2015) 126 (23): 2693.

https://doi.org/10.1182/blood.V126.23.2693.2693

Published: 2015

Journal Articles

Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation

Nancy M. Hardy, MD, Deborah Citrin, MD, Frances T. Hakim, PhD, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Stephanie Cotton, RN, Monica Cho, Daniel H. Fowler, MD, Juan C. Gea-Banacloche, MD, Noa G. Holtzman, MD, Karen A. Kurdziel, MD, Sarfraz Memon, MD, Steven Z. Pavletic, MD, Stefania Pittaluga, MD PhD, Jeremy J. Rose, BA, Claude Sportes, MD, Jennifer S. Wilder, RN, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2015) 126 (23): 1962.

https://doi.org/10.1182/blood.V126.23.1962.1962

Published: 2015

Journal Articles

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

David M. Hyman, MD, Eli Diamond, Vivek Subbiah, MD, Jean-Yves Blay, MD PhD, A. Craig Lockhart, Omar Abdel-Wahab, MD, Florin Sirzen, Maria Luisa Veronese, MD, Susan Frances Laserre, Elena Elez, Jose Baselga, MD PhD

Blood (2014) 124 (21): 635.

https://doi.org/10.1182/blood.V124.21.635.635

Published: 2014

Journal Articles

Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients

Blood (2014) 124 (21): 310.

https://doi.org/10.1182/blood.V124.21.310.310

Published: 2014

Journal Articles

Safety and Clinical Activity Of Crizotinib In Patients With ALK -Rearranged Hematologic Malignancies

Carlo Gambacorti-Passerini, MD, Keizo Horibe, MD, PhD, Fadi Braiteh, MD, CPI, Hui-qiang Huang, MD, PhD, Yuankai Shi, MD, PhD, Matthew H Taylor, MD, Nicoletta Brega, Jolanda Paolini, Paulina Selaru, Tae Min Kim, MD, PhD

Blood (2013) 122 (21): 4342.

https://doi.org/10.1182/blood.V122.21.4342.4342

Published: 2013

Journal Articles

Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival

Susanne M Rittig, MD, Maik Häntschel, MD, Katrin J Weimer, MD, Annkristin Heine, MD, Martin R Müller, MD, PhD, Wolfram Brugger, MD, Marius Horger, MD, Olga Maksimovic, MD, Arnulf Stenzl, MD, Ingmar Hoerr, Hans-Georg Rammensee, Tobias A.W. Holderried, MD, Lothar Kanz, MD, Steve Pascolo, Peter Brossart, MD

Blood (2013) 122 (21): 1040.

https://doi.org/10.1182/blood.V122.21.1040.1040

Published: 2013

Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood (2013) 122 (21): 368.

https://doi.org/10.1182/blood.V122.21.368.368

Published: 2013

Journal Articles

A Therapeutic Vaccine In Adult T-Cell Leukemia Patients With Autologous Dendritic Cells Pulsed With Peptides Corresponding To Tax-Specific Cytotoxic T Lymphocyte Epitopes

Tadafumi Iino, MD, Youko Suehiro, MD, PhD, Atsuhiko Hasegawa, PhD, Nobukazu Watanabe, MD, PhD, Ryuji Tanosaki, MD, PhD, Atae Utsunomiya, M.D., PhD, Masao Matsuoka, MD, PhD, Takanori Teshima, MD, PhD, Koichi Akashi, MD, PhD, Naokuni Uike, MD, PhD, Jun Okamura, MD, PhD, Mari Kannagi, MD, PhD

Blood (2013) 122 (21): 5130.

https://doi.org/10.1182/blood.V122.21.5130.5130

Published: 2013

Journal Articles

Durable Remission of Renal Cell Carcinoma After Donor Lymphocyte Infusion Is Unavoidably Linked with Graft Versus Host Disease As Illustrated by the Detection of Allo Reactive T Cells Recognizing a Novel Minor Histocompatibility Antigen Encoded by the FUCA2 Gene

Cornelis A.M. van Bergen, Elizabeth M.E. Verdegaal, PhD, Conny Hoogstraten, A.Q.M. Jeanne van Steijn, Linda de Quartel, Joan H. de Jong, Maaike Meyering, Marieke Griffioen, PhD, J.H.Frederik Falkenburg, MD, PhD, Susanne Osanto, MD, PhD

Blood (2012) 120 (21): 4467.

https://doi.org/10.1182/blood.V120.21.4467.4467

Published: 2012

Journal Articles

BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications

Nicola Lehners, MD, Mindaugas Andrulis, MD, David Capper, MD, Andreas von Deimling, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, Kai Neben, MD, Marc S Raab, MD

Blood (2012) 120 (21): 4040.

https://doi.org/10.1182/blood.V120.21.4040.4040

Published: 2012

Journal Articles

Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)

Ann M. Leen, PhD, Catherine M Bollard, MD, Adam M Mendizabal, Elizabeth J. Shpall, MD, Paul Szabolcs, MD, Joseph H. Antin, MD, Neena Kapoor, MD, Callie Heaton, Bambi J Grilley, Adrian P. Gee, PhD, Malcolm K. Brenner, MB, PhD, FRCP, FRCPath, Cliona M Rooney, PhD, Helen E. Heslop, MD

Blood (2010) 116 (21): 829.

https://doi.org/10.1182/blood.V116.21.829.829

Published: 2010

Journal Articles

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L Allen, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, Ian D. Lewis, MD, Miles Prince, MD, MRACMA, FRACP, FRCPA, Sonali Smith, MD, Elaine S Jaffe, MD, Susan Bates, MD

Blood (2009) 114 (22): 1657.

https://doi.org/10.1182/blood.V114.22.1657.1657

Published: 2009

NARROW

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients

Safety and Clinical Activity Of Crizotinib In Patients With ALK -Rearranged Hematologic Malignancies

Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

A Therapeutic Vaccine In Adult T-Cell Leukemia Patients With Autologous Dendritic Cells Pulsed With Peptides Corresponding To Tax-Specific Cytotoxic T Lymphocyte Epitopes

Durable Remission of Renal Cell Carcinoma After Donor Lymphocyte Infusion Is Unavoidably Linked with Graft Versus Host Disease As Illustrated by the Detection of Allo Reactive T Cells Recognizing a Novel Minor Histocompatibility Antigen Encoded by the FUCA2 Gene

BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications

Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only